BR112021001520A2 - neurotoxinas tetânicas peguiladas e tratamento de hipotonia - Google Patents

neurotoxinas tetânicas peguiladas e tratamento de hipotonia Download PDF

Info

Publication number
BR112021001520A2
BR112021001520A2 BR112021001520-5A BR112021001520A BR112021001520A2 BR 112021001520 A2 BR112021001520 A2 BR 112021001520A2 BR 112021001520 A BR112021001520 A BR 112021001520A BR 112021001520 A2 BR112021001520 A2 BR 112021001520A2
Authority
BR
Brazil
Prior art keywords
tent
peg
pegylated
composition
kda
Prior art date
Application number
BR112021001520-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas McLean
Peter Smooker
Luke Norbury
Peter Coloe
Russell Conduit
Anthony SASSE
Original Assignee
Snoretox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902779A external-priority patent/AU2018902779A0/en
Application filed by Snoretox Pty Ltd filed Critical Snoretox Pty Ltd
Publication of BR112021001520A2 publication Critical patent/BR112021001520A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24068Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
BR112021001520-5A 2018-07-31 2019-07-30 neurotoxinas tetânicas peguiladas e tratamento de hipotonia BR112021001520A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
AU2018902779 2018-07-31
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Publications (1)

Publication Number Publication Date
BR112021001520A2 true BR112021001520A2 (pt) 2021-04-20

Family

ID=69230503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021001520-5A BR112021001520A2 (pt) 2018-07-31 2019-07-30 neurotoxinas tetânicas peguiladas e tratamento de hipotonia

Country Status (12)

Country Link
US (1) US20210353724A1 (https=)
EP (2) EP3830110A4 (https=)
JP (3) JP2021533201A (https=)
KR (1) KR20210040407A (https=)
CN (2) CN120661638A (https=)
AU (1) AU2019315327B2 (https=)
BR (1) BR112021001520A2 (https=)
CA (2) CA3108079C (https=)
MX (1) MX2021001181A (https=)
NZ (1) NZ772266A (https=)
SG (1) SG11202100646SA (https=)
WO (1) WO2020024002A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240268895A1 (en) 2023-02-15 2024-08-15 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
GB9914861D0 (en) * 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
EP2425251B1 (en) * 2009-04-27 2017-10-25 Merz Pharma GmbH & Co. KGaA Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
LT2547364T (lt) * 2010-03-15 2017-03-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptidai, konjugatai ir vakcinos imunogeniškumo padidinimo būdas
WO2016001762A1 (en) 2014-07-02 2016-01-07 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
BR112018003782A2 (pt) * 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
JP2023513895A (ja) * 2020-02-03 2023-04-04 スノーレトックス リミテッド 組成物及び方法

Also Published As

Publication number Publication date
NZ772266A (en) 2022-09-30
MX2021001181A (es) 2021-04-19
JP2024014975A (ja) 2024-02-01
AU2019315327B2 (en) 2024-05-09
CN112638937A (zh) 2021-04-09
AU2019315327A1 (en) 2021-02-11
EP4134133A1 (en) 2023-02-15
JP2026026159A (ja) 2026-02-16
WO2020024002A1 (en) 2020-02-06
CA3167665A1 (en) 2020-02-06
KR20210040407A (ko) 2021-04-13
NZ789962A (en) 2025-07-25
JP7786745B2 (ja) 2025-12-16
US20210353724A1 (en) 2021-11-18
SG11202100646SA (en) 2021-02-25
CA3108079A1 (en) 2020-02-06
EP3830110A1 (en) 2021-06-09
CN120661638A (zh) 2025-09-19
CA3108079C (en) 2023-10-10
JP2021533201A (ja) 2021-12-02
EP3830110A4 (en) 2022-03-02
CN112638937B (zh) 2025-06-17

Similar Documents

Publication Publication Date Title
ES2339865T3 (es) Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de musculos espasticos.
DE69331901T2 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
ES2197688T3 (es) Vacuna meningococica multicomponente.
RU2487890C2 (ru) Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок
KR20210018205A (ko) 항원성 OspA 폴리펩타이드
BR112020019938A2 (pt) polipeptídeos antigênicos de vírus sincicial respiratório
US12233119B2 (en) Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
ES3061725T3 (en) A vaccine for protection against streptococcus suis
JP2026026159A (ja) Peg化破傷風神経毒素および筋緊張低下の治療
US20210100888A1 (en) Immunogenic complex for eliciting protective immunity against group b streptococcus
ES2969044T3 (es) Una vacuna para proteger contra Streptococcus suis
SG194420A1 (en) Antigen peptide and use thereof
HUT52787A (en) Process for production of biologically active peptides
ES2320392T3 (es) Epitopos protectores de la adenilato ciclasa-hemolisina (ac-hly), su aplicacion al tratamiento o a la prevencion de las infecciones por bordetella.
US20230057367A1 (en) Composition and method
WO2022207657A1 (en) Immunogenic fusion protein
Tarrab-Hazdai et al. Proteosome delivery of a protective 9B-antigen against Schistosoma mansoni
US20210379182A1 (en) Bivalent dengue/hepatitis b vaccines
JP2004041084A (ja) ヘリコバクター・ピロリ菌に対するワクチン用ペプチド、それをコードする遺伝子、その遺伝子が導入された形質転換体、及びそれらの利用方法
HK1227901A1 (en) Mutant fragments of ospa and methods and uses relating thereto
CZ20001399A3 (cs) Prostředky a způsoby pro systémové podání orálních vakcín a terapeutických činidel